NO970078L - Heterocykliske tachykinin reseptorantagonister - Google Patents

Heterocykliske tachykinin reseptorantagonister

Info

Publication number
NO970078L
NO970078L NO970078A NO970078A NO970078L NO 970078 L NO970078 L NO 970078L NO 970078 A NO970078 A NO 970078A NO 970078 A NO970078 A NO 970078A NO 970078 L NO970078 L NO 970078L
Authority
NO
Norway
Prior art keywords
heterocyclic
receptor antagonists
tachykinin receptor
tachykinin
aminoüpropane
Prior art date
Application number
NO970078A
Other languages
English (en)
Other versions
NO970078D0 (no
NO309651B1 (no
Inventor
Sung-Yong Cho
James Densmore Copp
Francis Orerenyo Ginah
Guy Joe Hansen
Philip Arthur Hipskind
Bret Eugene Huff
Michael John Martinelli
Michael Alexander Staszak
Roger William Tharp-Taylor
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO970078L publication Critical patent/NO970078L/no
Publication of NO970078D0 publication Critical patent/NO970078D0/no
Publication of NO309651B1 publication Critical patent/NO309651B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO970078A 1994-07-12 1997-01-09 (R)-3-(1H-indol-3-yl)-1-[N-(2-metoksybenzyl)acetylamino]-2-[N- NO309651B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27170894A 1994-07-12 1994-07-12
PCT/US1995/008300 WO1996001819A1 (en) 1994-07-12 1995-06-30 Heterocyclic tachykinin receptor antagonists

Publications (3)

Publication Number Publication Date
NO970078L true NO970078L (no) 1997-01-09
NO970078D0 NO970078D0 (no) 1997-01-09
NO309651B1 NO309651B1 (no) 2001-03-05

Family

ID=23036729

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970078A NO309651B1 (no) 1994-07-12 1997-01-09 (R)-3-(1H-indol-3-yl)-1-[N-(2-metoksybenzyl)acetylamino]-2-[N-

Country Status (25)

Country Link
US (1) US5530009A (no)
EP (1) EP0693489B1 (no)
JP (1) JPH10502640A (no)
CN (1) CN1067067C (no)
AT (1) ATE205491T1 (no)
AU (1) AU688072B2 (no)
BR (1) BR9508375A (no)
CA (1) CA2194471C (no)
CO (1) CO4410196A1 (no)
CZ (1) CZ288434B6 (no)
DE (1) DE69522619T2 (no)
DK (1) DK0693489T3 (no)
ES (1) ES2163475T3 (no)
FI (1) FI970107A (no)
HU (1) HUT77948A (no)
IL (1) IL114474A (no)
MX (1) MX9700271A (no)
NO (1) NO309651B1 (no)
NZ (1) NZ289652A (no)
PL (1) PL180866B1 (no)
PT (1) PT693489E (no)
RU (1) RU2151769C1 (no)
TR (1) TR199500844A1 (no)
WO (1) WO1996001819A1 (no)
ZA (1) ZA955639B (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403577B1 (en) 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
US6869957B1 (en) 1993-11-17 2005-03-22 Eli Lilly And Company Non-peptide tachykinin receptor antagonists
AU5966096A (en) * 1995-06-09 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
EP0761219A1 (en) * 1995-08-21 1997-03-12 Eli Lilly And Company 2-Acylaminopropanamines as growth hormone secretagogues
WO1997023455A1 (en) * 1995-12-21 1997-07-03 Eli Lilly And Company Processes for preparing non-peptidyl tachykinin receptor antagonists
CA2247822A1 (en) * 1996-03-11 1997-09-18 Smriti Iyengar Methods of treating or preventing interstitial cystitis
US6239144B1 (en) 1997-04-03 2001-05-29 Eli Lilly And Company Methods of treating bone loss
WO1998052890A1 (en) * 1997-05-21 1998-11-26 Eli Lilly And Company 3-arylpropylamino neuropeptide y receptor antagonists
AU8693398A (en) * 1997-08-06 1999-03-01 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
ID24309A (id) * 1997-08-06 2000-07-13 Lilly Co Eli 2-asilaminopropanamina sebagai antagonis reseptor tachykinin
GB2333785B (en) 1998-01-28 2002-07-31 Baker Hughes Inc Remote actuation of downhole tools using vibration
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
CA2389306C (en) 1999-11-03 2010-03-30 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
GB9927125D0 (en) 1999-11-16 2000-01-12 Univ Reading The Placental human neurokinin B precursor
CA2415532C (en) 2000-07-11 2010-05-11 Albany Molecular Research, Inc. Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
EP1556054A4 (en) * 2002-05-29 2007-09-05 Univ California ANTAGONIZING NK1 RECEPTORS RESTRICT DRUG ABUSE
MX2007000428A (es) 2004-07-15 2008-03-05 Amr Technology Inc Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina.
ATE478075T1 (de) 2005-03-08 2010-09-15 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
MX2008000717A (es) 2005-07-15 2008-03-18 Amr Technology Inc Tetrahidrobenzazepinas substituidas con arilo y heteroarilo y uso de las mismas para bloquear la reabsorcion de norepinefrina, dopamina, y serotonina.
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
KR101591656B1 (ko) 2007-01-10 2016-02-19 엠에스디 이탈리아 에스.알.엘. 폴리(ａｄｐ-리보오스) 폴리머라아제(ｐａｒｐ) 억제제로서의 아미드 치환된 인다졸
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
CN102638982B (zh) 2009-05-12 2015-07-08 百时美施贵宝公司 (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途
DK2429296T3 (en) 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2011292261B2 (en) 2010-08-17 2015-05-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
WO2012027236A1 (en) 2010-08-23 2012-03-01 Schering Corporation NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2699568A1 (en) 2011-04-21 2014-02-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CA2892361A1 (en) 2012-11-28 2014-06-05 Merck Sharp & Dohme Corp. Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
AU2013361694B2 (en) 2012-12-20 2017-10-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3367985D1 (en) * 1982-09-18 1987-01-15 Lillywhites Cantabrian Ltd Display unit
US5331089A (en) 1988-03-25 1994-07-19 Merck Sharpe & Dohme, Ltd. Peptides useful as tachykinin agonists
US5182282A (en) * 1989-04-28 1993-01-26 Roussel Uclaf 4-Benzyl-1H-indole derivatives
AU687754B2 (en) 1990-08-31 1998-03-05 Warner-Lambert Company Tachykinin antagonists
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
FR2676053B1 (fr) * 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH06509087A (ja) 1991-07-05 1994-10-13 メルク　シヤープ　エンド　ドーム　リミテツド 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用
EP0533280B2 (en) 1991-09-20 2004-12-01 Glaxo Group Limited Novel medical use for tachykinin antagonists
US5328927A (en) 1992-03-03 1994-07-12 Merck Sharpe & Dohme, Ltd. Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them
US5444074A (en) * 1992-04-15 1995-08-22 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
WO1994001402A1 (en) 1992-07-13 1994-01-20 Merck Sharp & Dohme Limited Heterocyclic amide derivatives as tachykinin derivatives
FR2696178B1 (fr) 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
US5344830A (en) 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
CA2150992A1 (en) * 1994-06-10 1995-12-11 Philip Arthur Hipskind Cyclohexyl tachykinin receptor antagonists

Also Published As

Publication number Publication date
EP0693489B1 (en) 2001-09-12
ATE205491T1 (de) 2001-09-15
CA2194471C (en) 2005-04-12
MX9700271A (es) 1997-05-31
ES2163475T3 (es) 2002-02-01
US5530009A (en) 1996-06-25
DE69522619D1 (de) 2001-10-18
FI970107A (fi) 1997-03-07
FI970107A0 (fi) 1997-01-10
JPH10502640A (ja) 1998-03-10
HUT77948A (hu) 1998-12-28
RU2151769C1 (ru) 2000-06-27
TR199500844A1 (tr) 1996-10-21
CO4410196A1 (es) 1997-01-09
DE69522619T2 (de) 2002-06-27
AU688072B2 (en) 1998-03-05
BR9508375A (pt) 1997-10-28
WO1996001819A1 (en) 1996-01-25
EP0693489A1 (en) 1996-01-24
PL318327A1 (en) 1997-06-09
NO970078D0 (no) 1997-01-09
CN1067067C (zh) 2001-06-13
IL114474A (en) 1999-12-31
DK0693489T3 (da) 2001-11-12
ZA955639B (en) 1997-01-06
PT693489E (pt) 2002-01-30
CN1157615A (zh) 1997-08-20
CZ5797A3 (en) 1997-04-16
NO309651B1 (no) 2001-03-05
IL114474A0 (en) 1995-11-27
CA2194471A1 (en) 1996-01-25
NZ289652A (en) 1998-05-27
HU9700069D0 (en) 1997-02-28
PL180866B1 (pl) 2001-04-30
AU2956095A (en) 1996-02-09
CZ288434B6 (en) 2001-06-13

Similar Documents

Publication Publication Date Title
TR199500844A1 (tr) Heterosiklik takikininin reseptör antagonistleri.
DE69724644D1 (de) 1,5-benzodiazepinderivate
ATE360617T1 (de) Benzoheterocyclische verbindungen verwendbar als vasopressin- oder oxytocin-modulatoren
DE69734321D1 (de) Non-peptidische vasopressin via antagonisten
IS5539A (is) 4-(2-ketó-1-bensímidazólinýl) píperidín efnasambönd sem mótlyf fyrir orl 1-viðtaka
ATE408611T1 (de) Piperidine als nmda-rezeptorantagonisten
DK0957099T3 (da) Heterocykliske carboxamider
HU9301602D0 (en) Angiotensine 11 antagonists
ATE219077T1 (de) Endothelin antagoniste
MY117680A (en) 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)- piperidine derivatives
DK0952154T3 (da) N-acyl- og N-aroylaralkylamider
DK0967207T3 (da) Nitron-derivater, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger indeholdende derivaterne
DK0630893T3 (da) N,N'-disubstitueret amidderivat
NO993372D0 (no) Substituerte 4-(6-fluor-(1H)-indol-3-yl)-1,2,3,6-tetrahydropyridin for behandling av CNS-forstyrrelser
FI942798A (fi) Loracarbef-hydrokloridi-C1-C3-alkoholisolvaatit ja niiden käyttö
CO4970784A1 (es) Antagonistas del receptor de fibrinogen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN DECEMBER 2003